Clinical trial · Observational
NANOTECH RCC Biomarkers
Nanotech Biomarkers For Renal Cancer Intervention: Clinical Validation & Utility
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The incidence of renal cell carcinoma (RCC or kidney cancer) in men exceeds that of pancreatic cancer or leukemia. In women, the incidence of RCC is similar to that of leukemia, ovarian, or pancreatic cancer; thus, RCC is significant health issue. This study focuses on identifying specific molecules \[biomarkers\] of RCC that can be used to develop a reliable low-cost screening method at the point of service. If successful, our method would provide a diagnostic test to distinguish benign kidney masses from malignant ones, eliminating the need to surgically remove a kidney with a benign tumor.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Renal Cell Cancer | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
| Renal Cell Carcinoma | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Imaged renal mass cohort
- description
- Subjects undergoing surgery for an kidney tumor identified radiologically.
- label
- control cohort
- description
- Subjects undergoing surgery for any kind of cancer other than kidney.
Primary outcomes (2)
- measure
- Urine AQP1
- timeFrame
- 28 days
- description
- Assay results will be compared to the pathology report for the excised renal mass and the ICD10 codes.
- measure
- PLIN2 concentration
- timeFrame
- 28 days
- description
- Assay results will be compared to the pathology report for the excised renal mass and the ICD10 codes.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Patients 18 years of age and older undergoing surgery. Patient samples are divided into 2 groups based on their surgery: Patients with an imaged renal mass, encompassing about 300 patients/year (about 1200 total) of both malignant (about 80-85% of time) and benign (about 15-20% of time), and patients with non-kidney cancers, encompassing about 6,000 patients/year (about 24,000 total), Exclusion Criteria: Age \<18 years and prisoners.
References
Publications (0)
Data not yet available